Última Hora: "Portugal é o país que mais subiu no ranking mundial da competitividade - Expresso" Wed, 23 May 2018 20:01:00 GMT    "Obras na A1 entre Sacavém e Vila Franca a partir de segunda-feira - TVI24" Wed, 23 May 2018 16:47:00 GMT    "Volume de exportações de Braga cresceu 35% - Expresso" Wed, 23 May 2018 19:25:00 GMT    "Portugal deve rever lei laboral para promover contratos permanentes, afirma Bruxelas - Observador" Wed, 23 May 2018 13:42:00 GMT    "Ministro adjunto garante que nunca se reuniu com a China Three Gorges - Renascença" Wed, 23 May 2018 13:07:04 GMT   "" Wed, 23 May 2018 20:56:45 GMT    "Comida para caridade abandonada em monte de Guimarães - PT Jornal" Wed, 23 May 2018 14:09:28 GMT    "'Jackpot' de 57 milhões de euros no próximo sorteio do Euromilhões - Correio da Manhã" Tue, 22 May 2018 21:20:27 GMT    "Ferroviários fazem greve a 4 de junho contra agente único nos comboios - Observador" Wed, 23 May 2018 17:32:21 GMT    "Novas regras de proteção de dados: Da myTaxi à Nos, as empresas estão prontas para a mudança? - ECO Economia Online" Wed, 23 May 2018 17:10:29 GMT      Para mais notícias, clique aqui.

Área de Acesso
       
       
Lembrar Sempre 
(Login BolsaPT & Canal Forex)

Mostrar Notícias:
 Ver notícias de outros activos

Pesquisa de notícias relativas à acção Sepracor Inc. (ordenadas pela data):


Business Wire (press release)

Entasis Therapeutics Appoints David C. Hastings to Board of Directors
Business Wire (press release)
BUSINESS WIRE)--Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced the appointment of David C. Hastings to the company's Board of ...

e mais »

Business Wire (press release)

Rodin Therapeutics Expands Leadership Team, Adding Extensive Experience in Clinical and Business Development
Business Wire (press release)
She then joined Sunovion Pharmaceuticals, Inc. (formerly Sepracor), moving through positions of increasing responsibility into the role of vice president for corporate development and licensing. Sullivan played an instrumental role in the company's ...


Form DEF 14A Aralez Pharmaceuticals For: Jun 29
StreetInsider.com
You are cordially invited to attend the 2018 Annual Meeting of Shareholders (the "Meeting") of Aralez Pharmaceuticals Inc. ("Aralez" or the "Company") on Friday, June 29, 2018, at 9:00 a.m. (Eastern Standard Time) at the offices of Stikeman Elliott LLP ...


Innovative Add-On Treatments for Schizophrenia: May 2018
Healio
Sponsorship Statement: This CME activity is jointly sponsored by AKH Inc., Advancing Knowledge in Healthcare and Psychiatric Annals. ... Faculty members report the following financial relationships: Andrew A. Nierenberg, MD, has disclosed the following ...


Allergy Treatment Market to See Incredible Growth During 2016-2026
The Financial Analyst
... market are Allergy therapeutics, Allergopharma, Allergon AB, Alerpharma S.A, Allergan, Inc., Genentech Inc., Schering-Plough Corporation, McNeil Consumer Healthcare, Collegium Pharmaceutical, Inc., Meda Pharmaceuticals, Inc, Sepracor, Inc. and ...

e mais »

Business Wire (press release)

Kala Pharmaceuticals Strengthens Commercial Organization in Preparation for First Product Launch
Business Wire (press release)
BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of product candidates using its proprietary mucus-penetrating particle (MPP) technology, today announced the ...


Global Loratadine Market 2018 Share- Sandoz, Mylan and Sepracor
The Columnist
... Loratadine Market based on Key Players: This part figures out the Loratadine market on the basis of top manufacturers which includes Pfizer, Teva, Apollo Pharmaceuticals, GSK, Sepracor, Novartis India Limited, Sandoz, Mylan and Mayne Pharma Inc.

e mais »

United States Asthma Medication Market Report 2018-2025
The Mobile Herald
Inc, AstraZeneca plc, Roche Holdings Ltd, Genentech Inc, Sepracor, Inc, Schering-Plough Corp, Sanofi-Aventis, Theravance Inc. On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type ...


BSA bureau (press release)

Sumitomo Dainippon appoints Nomura as President & CEO
BSA bureau (press release)
In 2010, Sunovion (formerly Sepracor Inc.), was acquired by Sumitomo Dainippon. Nomura took the position of the Vice Chair, Executive Vice President and CFO, Sunovion Pharmaceuticals Inc. in 2012. Following 2014, he became associated with the ...

e mais »

Allergy Treatment Market: Global Industry Analysis and Opportunity Assessment 2016-2026
Healthcare Journal
... market are Allergy therapeutics, Allergopharma, Allergon AB, Alerpharma S.A, Allergan, Inc., Genentech Inc., Schering-Plough Corporation, McNeil Consumer Healthcare, Collegium Pharmaceutical, Inc., Meda Pharmaceuticals, Inc, Sepracor, Inc. and ...

e mais »

Business Wire (press release)

Kala Pharmaceuticals Appoints Eric Trachtenberg as General Counsel and Corporate Secretary
Business Wire (press release)
Prior to Auxilium, he was Vice President, General Counsel and Corporate Secretary of Enobia Pharma, Inc. Prior to that, Mr. Trachtenberg served as Vice President and Associate General Counsel of Sepracor Inc. (now known as Sunovion Pharmaceuticals ...

e mais »

Business Wire (press release)

BioClin Therapeutics Appoints Graeme Currie, Ph.D., as Chief Operating Officer and Esteban (Steve) Abella, MD, as ...
Business Wire (press release)
Dr. Currie has over 25 years of drug development experience in both pharmaceutical and biotechnology companies, having held senior leadership roles at Dynavax Technologies Corp., Regeneron Pharmaceuticals, Sepracor Inc. and PDL Biopharma.

e mais »

Kala Pharmaceuticals Appoints Todd Bazemore as Chief Operating Officer
Business Wire (press release)
Prior to joining Dyax, Todd was at Sunovion Pharmaceuticals, Inc. (previously Sepracor Inc., prior to its acquisition by Sumitomo Dainippon Pharma Co., Ltd), where he served in several roles of increasing responsibility including Vice President ...

e mais »

Bellicum Pharmaceuticals Appoints Edmund P. Harrigan, MD to its Board of Directors
GlobeNewswire (press release)
In addition to his experience at Pfizer, Dr. Harrigan previously served as President & CEO of Karuna Pharmaceuticals, and in senior clinical leadership positions at Neurogen Corp. and Sepracor, Inc. Prior to entering the pharmaceutical industry in 1990 ...

e mais »

Newcanaanitect.com

Global Desloratadine Market 2018: Pfizer, Teva, Wante Pharmaceutical, Novartis India Limited, Mylan
Newcanaanitect.com
Moreover, the list of major companies/competitors is also present including Pfizer, Teva, Wante Pharmaceutical, Novartis India Limited, Mylan, Sepracor, Sandoz, Apollo Pharmaceuticals, GSK, Mayne Pharma Inc . The competition data allows users to gauge ...


Form DEF 14A Spero Therapeutics, Inc. For: Jun 05
StreetInsider.com
You are cordially invited to attend the 2018 annual meeting of stockholders of Spero Therapeutics, Inc. to be held at 9:00 a.m. ET on Tuesday, June 5, 2018 at the offices of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. at One Financial Center ...

e mais »

Drugmakers Duped Medicaid Rebate Regulators, 3rd Circ. Told
Law360
Law360, Philadelphia (April 12, 2018, 4:25 PM EDT) -- A pharmaceutical executive urged the Third Circuit on Wednesday to revive his suit alleging Allergan Inc. and other companies shorted the federal government on drug rebate payments, arguing that the ...

e mais »

Global Desloratadine Market Market | Trends, Share, Growth Rate, Opportunities and Market Forecast 2018-2025
The Mobile Herald
Worldwide Desloratadine Market Market 2018 Report presents a professional and deep analysis on the present state of Desloratadine Market Market. The study of Desloratadine Market industry is very important to enhance business productivity and for the ...

e mais »

Kala Pharmaceuticals Appoints Andrew I. Koven to Board of Directors
Business Wire (press release)
From 2007-2010, Mr. Koven served as Executive Vice President, General Counsel and Corporate Secretary at Sepracor Inc., where he was responsible for the company's legal and government affairs departments and Corporate Secretarial function until its ...

e mais »

Spero Announces Appointment of David P. Southwell to its Board of Directors
GlobeNewswire (press release)
01, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant bacterial infections, announced ...

e mais »

Minerva Neurosciences Names Richard Russell President
GlobeNewswire (press release)
11, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the appointment of Rick Russell ...

e mais »

Sunovion Pharmaceuticals Inc. Announces Company Name Change
Business Wire (press release)
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sunovion Pharmaceuticals Inc. (Sunovion), formerly Sepracor Inc. (Sepracor), announced today that it has formally changed its name. The change occurs on approximately the one year anniversary of the ...

e mais »

The Boston Globe

Japanese executives ponder investing in Mass.
The Boston Globe
They visited a giant laboratory in Cambridge shared by emerging biotech companies and walked the life sciences mecca that is Kendall Square. They met with government officials who want to lure foreign companies to Massachusetts. They even saw the ...


Allergy Treatment Market - Evolving Industry Trends and Key Insights by 2024
Digital Journal
... are Allergopharma, Allergy Therapeutics, Alerpharma S.A, Allergon AB, Genentech Inc., Allergan, Inc., McNeil Consumer Healthcare, Schering-Plough Corporation, Meda Pharmaceuticals, Inc, Collegium Pharmaceutical, Inc., Vicks, and Sepracor, Inc.

e mais »

Dainippon Sumitomo Pharma to Acquire Sepracor for US $23.00 Per Share in an All-Cash Tender Offer Valued at ...
FierceBiotech
BUSINESS WIRE)--Dainippon Sumitomo Pharma Co., Ltd. ("DSP", TSE: 4506) and Sepracor Inc. ("Sepracor", Nasdaq: SEPR) today announced that they have entered into a definitive agreement pursuant to which DSP will acquire Sepracor for approximately ...
Drugmaker Sepracor Accepts $2.6B Buyout Offer from Japan's DainipponXconomy

todos os 485 artigos de notícias »

Xencor Appoints Richard Ranieri to Board of Directors
PR Newswire (press release)
Prior to this role he served as executive vice president, human resources at Dendreon Corporation, and executive vice president, human resources & administration at Sepracor, Inc. Earlier in his career, Mr. Ranieri served in executive positions at ...

e mais »

GlobeNewswire (press release)

VBL Therapeutics Announces the Appointments of Susan Kelley and David Hastings to Its Board of Directors
GlobeNewswire (press release)
... 2003 Mr. Hastings served as Vice President, Chief Financial Officer and Treasurer of ArQule Inc. Prior to his employment with ArQule, Mr. Hastings was Vice President and Corporate Controller at Genzyme Inc., and Director of Finance at Sepracor ...

e mais »

Business Wire (press release)

Flex Pharma Reports Third Quarter 2017 Financial Results
Business Wire (press release)
Flex Pharma, Inc. (NASDAQ:FLKS), a clinical-stage biotechnology company that is developing innovative and proprietary treatments in Phase 2 randomized, controlled trials for cramps and spasticity associated with severe neurological diseases such as ...

e mais »

Business Wire (press release)

Flex Pharma Reports Year End 2017 Financial Results
Business Wire (press release)
BOSTON--(BUSINESS WIRE)--Flex Pharma, Inc. (NASDAQ: FLKS), a clinical-stage biotechnology company that is developing innovative and proprietary treatments in Phase 2 randomized, controlled trials for cramps and spasticity associated with severe ...

e mais »

Zacks Small Cap Research (press release)

PULM: Business And Financial Update For Third Quarter 2017
Zacks Small Cap Research (press release)
Prior to joining Veristat, he served as Senior Vice President, Development and Chief Medical Officer of Momenta Pharmaceuticals, Senior Vice President, Medical Affairs at Sepracor Pharmaceuticals, and Head of Medical Affairs at Millennium ...


Largura do Site:

 Imagem de Fundo:

Copyright@1998-2018 - BolsaPT.com, todos os direitos reservados.
Fórum de Bolsa Cotações de Bolsa Notícias de Bolsa Chat de Bolsa Disclaimer Recursos para Webmasters